M2613 is a nonsteroidal estrogen derived from triphenylbromoethylene which was studied for the treatment of breast cancer in women in the 1940s, but was never marketed.[1][2]
 | |
| Clinical data | |
|---|---|
| Other names | M-2613; Methoxyethoxy-triphenylbromoethylene |
| Drug class | Nonsteroidal estrogen |
| Identifiers | |
| |
| CAS Number | |
| Chemical and physical data | |
| Formula | C23H21BrO2 |
| Molar mass | 409.323 g·mol−1 |
See also
editReferences
edit- ^ Walpole AL, Paterson E (October 1949). "Synthetic oestrogens in mammary cancer". Lancet. 2 (6583): 783–6. doi:10.1016/s0140-6736(49)91370-7. PMID 15391512.
- ^ Jordan VC (February 2015). "The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer". Endocr. Relat. Cancer. 22 (1): R1–31. doi:10.1530/ERC-14-0448. PMC 4494663. PMID 25339261.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |